Carbapenemase Inhibitors: Updates on Developments in 2021

Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avibactam, relebactam and vaborbactam,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bou Zerdan, Maroun, Al Hassan, Sally, Shaker, Waleed, El Hajjar, Rayan, Allam, Sabine, Bou Zerdan, Morgan, Naji, Amal, Zeineddine, Nabil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365662/
https://www.ncbi.nlm.nih.gov/pubmed/35974805
http://dx.doi.org/10.14740/jocmr4764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365662/
https://www.ncbi.nlm.nih.gov/pubmed/35974805
http://dx.doi.org/10.14740/jocmr4764

Ejemplares similares